Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

被引：35
|
作者：
Qiu, Zhenbin [1 ]
Chen, Zihao [1 ]
Zhang, Chao [1 ]
Zhong, Wenzhao [1 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2019年 / 8卷 / 01期
关键词：
Checkpoint inhibitors; NSCLC; Novel therapies; OPEN-LABEL; BRAIN METASTASES; 1ST-LINE TREATMENT; PLUS TREMELIMUMAB; PEMBROLIZUMAB; NIVOLUMAB; CHEMOTHERAPY; THERAPY; IMMUNOTHERAPY; MULTICENTER;
D O I：
10.1186/s40164-019-0143-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival benefits for wild-type advanced NSCLC patients with acceptable adverse effects. Though beneficiary population is limited from monotherapy, combination strategies are expanding indicators. Retrospective evidences suggested ICIs are also potentially useful for brain metastasis. Furthermore, the combination of ICIs and surgery are to prolong progression free survival time for local advanced patients. Additionally, novel agents targeting in immune checkpoints other than PD-1/L1 demonstrated potential values in anticancer immunity. Herein, we summarize the novel therapies of checkpoint inhibitors in NSCLC treatment and some other potential immunotherapy to provide a conspectus for novel immunotherapy in NSCLC and perspective for the future in anti-cancer treatment.
引用
收藏
页数：19
相关论文
共 50 条
  • [1] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Zhenbin Qiu
    Zihao Chen
    Chao Zhang
    Wenzhao Zhong
    [J]. Experimental Hematology & Oncology, 8
  • [2] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    [J]. ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [3] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    [J]. ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [4] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
  • [5] Highlights on immune checkpoint inhibitors in non-small cell lung cancer
    Shen, Meng
    Ren, Xiubao
    [J]. TUMOR BIOLOGY, 2017, 39 (03)
  • [6] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    [J]. BULLETIN DU CANCER, 2016, 103 : S138 - S143
  • [7] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    [J]. CANCER, 2018, 124 (02) : 248 - 261
  • [8] Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
    Bote, Helena
    Mesas, Andres
    Baena, Javier
    Herrera, Mercedes
    Paz-Ares, Luis
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 289 - 300
  • [9] Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
    Fonseca, A.
    Silva, E.
    Coutinho, D.
    Campainha, S.
    Dias, M.
    Barroso, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S339 - S340
  • [10] Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Ushio, Ryota
    Murakami, Shuji
    Saito, Haruhiro
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
12345